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Biofilm infec tions present a ma jor public heal th threat . In the United Sta tes alone, biofilm
infect ions are impl ica ted in up to 550,000 yearly fatal it ies wi th an est ima ted annual cost of $94
bill ion1,2. Biofi lm infec tions are d ifficult to tr eat , as biofilm-se cret ing bac teri a are highly res istan t
to host immune responses. We hypothesi ze that Saf e Ac id Te chnology (SAT), a unique ac id
formulation, may reduce the risk of biofilm infections while maximizing patient safety.
INTRODUCTION
Anti-biofilm testing was administered by the Montana State University  Center for BioFilm Engineering 
using a single species (Pseudomonas aeruginosa ) biofilm grown in the CDC reactor according to  ASTM 
E2871-12 on polycarbonate coupons. After establishing biofilms, the polycarbonate coupons were exposed 
to  SAT formulations for multiple exposure times in  varied concentrations. 
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RESULTS
CONCLUSION
Biofilm Establishment and Proliferation
The current recommended treatment for biofilm infections involves long-term antibiotic 
therapy, which may reduce bacteria in  the perioperative period but has limited ability  to  address 
bacterial resistance and penetrate biofilms. Safe Acid Technology, which demonstrates potent 
anti-biofilm action along with non-toxicity  to  human mucosa, may prove a superior and cost-
effective alternative to  the current treatment paradigm for biofilm infections. 
Fig  1 .  Resu lts o f Treatmen ts (erro r b ars are ± 1  SD fro m the mean ).
METHODS & MATERIALS
CDC Reactor
Log reductions of biofilm ranged from 3.61 at concentrations of C50 to  4 .82 at C25. This was 
compared to  biofilm concentration of Log 8.62 on control 
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DISCUSSION
Despite Safe Acid Technology’s disinfectant power, it does not irritate or harm human skin or mucosa. 
SAT has passed the EPA’s stringent toxic six-pack criteria assessing toxicity  and irritation to  human 
skin. Additionally , all of SAT’s ingredients are listed on the FDA’s “generally  recognized as safe” list. 
There is no special disposal protocol necessary for SAT as it breaks down into harmless inorganic 
compounds and is nontoxic. The combination of extreme acidification and non-toxicity  opens the 
possibility  of a wide range of applications for Safe Acid Technology including:
WOUND CARE
• Wound healing is a complex physiological process. The presence of 
biofilms and infectious agents in  these wounds can be catastrophic. The 
surface pH of a wound has been demonstrated to  influence wound 
healing, as it helps control infection in  addition to  increasing 
antimicrobial activity , oxygen release, angiogenesis, protease activity , and 
bacterial toxicity3. SAT could be applied to  wounds to  achieve a sterile 
environment ideal for healing while avoiding harm to patient tissues.
• Additionally , SAT has demonstrated up to  a seven log reduction 
(99.999999%) in  the five most commonly isolated bacterial species in  
chronic wounds (Staphylococcus aureus, Enterococcus faecalis, 
Pseudomonas aeruginosa , coagulase-negative Staphylococci, and 
Proteus species)5. SAT could be used in  a chronic setting in  conjunction 
with normal wound care and dressing changes.
PRE-OPERATIVE SKIN ANTISEPTIC
• Biofilms are well-adapted to  growth on all physiological tissues, as well 
as implantable and injectable materials. In  a surgical setting, these 
infections are often devastating. The current standard of care for 
prophylactic surgical skin prep includes topical application 
chlorohexidine gluconate and iodine7. The latter of which has been 
shown to be inactivated by exposure to  blood and serum6.
Chlorohexidine gluconate has been shown to be unsafe for ears, eyes, 
and mouth, and may not be used for preparation of facial procedures. In  
contrast, SAT has been shown to be safe on all mucous membranes 
including ear, mouth, and eye membranes. 
• Safe Acid Technology could be used as a pre-operative skin antiseptic to  
minimize peri-operative surgical site infections. 
Fig  2  (Pu p p G, Koivu n en R.  How	to 	Assess	 th e	
Bacterial 	 Bu rden 	o f	DFUs.	P o d 	To d a y	20 12 ;	6 2-68.  
Fig  3  (Pu p p G, Koivu n en R.  How	to 	Assess	 th e	
Bacterial 	 Bu rden 	o f	DFUs.	P o d 	To d a y	20 12 ;	6 2-68.  
Fig  4 (Ad ap ted  fro m Wip f et al,  20 08 .5)
